Keywords: Amgen, Prolia, Bone mineral desnity, Bone loss, FDA, USA, GlaxoSmithKline

Amgen’s Prolia increases bone mineral density over eight; new indications approved

Article | 20 September 2011

Print This

The world’s largest biotechnology firm, USA-based Amgen (Nasdaq: AMGN) says that new long-term data show that Prolia (denosumab) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in